Study of XELOX With Cetuximab in Advanced Gastric Cancer
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The combination of capecitabine and oxaliplatin as 'backbone' regimen, adding a newer
biologic agent, cetuximab, is a reasonable strategy of further chemotherapy development in
advanced gastric cancer, which is the investigators study rationale.